Published in Nat Rev Cancer on February 11, 2010
Bicalutamide in Treating Patients With Metastatic Breast Cancer | NCT00468715
Androgen receptor driven transcription in molecular apocrine breast cancer is mediated by FoxA1. EMBO J (2011) 1.72
Minireview: The androgen receptor in breast tissues: growth inhibitor, tumor suppressor, oncogene? Mol Endocrinol (2012) 1.44
Estrogen receptors and human disease: an update. Arch Toxicol (2012) 1.22
Transcription-induced DNA double strand breaks: both oncogenic force and potential therapeutic target? Clin Cancer Res (2011) 1.21
Estrogen signaling and the DNA damage response in hormone dependent breast cancers. Front Oncol (2014) 1.18
Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications. Oncoimmunology (2015) 1.06
Targeting Akt3 signaling in triple-negative breast cancer. Cancer Res (2013) 1.06
Polygenic modeling of genome-wide association studies: an application to prostate and breast cancer. OMICS (2011) 1.02
The G protein-coupled receptor 30 is up-regulated by hypoxia-inducible factor-1alpha (HIF-1alpha) in breast cancer cells and cardiomyocytes. J Biol Chem (2011) 0.98
Estrogen receptor alpha drives proliferation in PTEN-deficient prostate carcinoma by stimulating survival signaling, MYC expression and altering glucose sensitivity. Oncotarget (2015) 0.94
Familial risk and familial survival in prostate cancer. World J Urol (2011) 0.94
Estrogen receptor beta as a novel target of androgen receptor action in breast cancer cell lines. Breast Cancer Res (2014) 0.92
Sirtuin 1 (SIRT1) and steroid hormone receptor activity in cancer. J Endocrinol (2011) 0.91
Estrogen receptor beta 2 is associated with poor prognosis in estrogen receptor alpha-negative breast carcinoma. J Cancer Res Clin Oncol (2013) 0.91
Multiple roles of COUP-TFII in cancer initiation and progression. J Mol Endocrinol (2012) 0.89
Estrogen receptor β activation impairs prostatic regeneration by inducing apoptosis in murine and human stem/progenitor enriched cell populations. PLoS One (2012) 0.89
A high-fat diet containing whole walnuts (Juglans regia) reduces tumour size and growth along with plasma insulin-like growth factor 1 in the transgenic adenocarcinoma of the mouse prostate model. Br J Nutr (2012) 0.88
Phase two steroid metabolism and its roles in breast and prostate cancer patients. Front Endocrinol (Lausanne) (2013) 0.86
Estrogen receptors and their implications in colorectal carcinogenesis. Front Oncol (2015) 0.86
Expression of androgen receptor splice variants in clinical breast cancers. Oncotarget (2015) 0.85
Regulators of genetic risk of breast cancer identified by integrative network analysis. Nat Genet (2015) 0.85
Silencing of GSTP1, a prostate cancer prognostic gene, by the estrogen receptor-β and endothelial nitric oxide synthase complex. Mol Endocrinol (2011) 0.83
The evolving paradigm of cell-nonautonomous UPR-based regulation of immunity by cancer cells. Oncogene (2015) 0.83
Assay reproducibility and interindividual variation for 15 serum estrogens and estrogen metabolites measured by liquid chromatography-tandem mass spectrometry. Cancer Epidemiol Biomarkers Prev (2014) 0.82
Tissue-of-origin-specific gene repositioning in breast and prostate cancer. Histochem Cell Biol (2016) 0.82
Identification of shared and unique susceptibility pathways among cancers of the lung, breast, and prostate from genome-wide association studies and tissue-specific protein interactions. Hum Mol Genet (2015) 0.81
A Drosophila Genome-Wide Screen Identifies Regulators of Steroid Hormone Production and Developmental Timing. Dev Cell (2016) 0.79
Prostate cancer incidence and survival in immigrants to Sweden. World J Urol (2013) 0.78
Analysis of tumor suppressor genes based on gene ontology and the KEGG pathway. PLoS One (2014) 0.78
The stromal genome heterogeneity between breast and prostate tumors revealed by a comparative transcriptomic analysis. Oncotarget (2015) 0.78
Stem Cell Antigen-1 Identifies a Distinct Androgen-Independent Murine Prostatic Luminal Cell Lineage with Bipotent Potential. Stem Cells (2015) 0.78
Steroid signaling activation and intracellular localization of sex steroid receptors. J Cell Commun Signal (2010) 0.77
Teasing out the role of aromatase in the healthy and diseased testis. Spermatogenesis (2011) 0.77
Fas Activated Serine-Threonine Kinase Domains 2 (FASTKD2) mediates apoptosis of breast and prostate cancer cells through its novel FAST2 domain. BMC Cancer (2014) 0.77
Analysis of candidate genes has proposed the role of y chromosome in human prostate cancer. Iran J Cancer Prev (2014) 0.76
Liver metastatic disease: new concepts and biomarker panels to improve individual outcomes. Clin Exp Metastasis (2016) 0.76
Slug contributes to cancer progression by direct regulation of ERα signaling pathway. Int J Oncol (2015) 0.75
NRBP1 is downregulated in breast cancer and NRBP1 overexpression inhibits cancer cell proliferation through Wnt/β-catenin signaling pathway. Onco Targets Ther (2015) 0.75
mRNA expression of steroidogenic enzymes, steroid hormone receptors and their coregulators in gastric cancer. Oncol Lett (2017) 0.75
Sex steroid metabolism in benign and malignant intact prostate biopsies: individual profiling of prostate intracrinology. Biomed Res Int (2014) 0.75
A network based approach to drug repositioning identifies plausible candidates for breast cancer and prostate cancer. BMC Med Genomics (2016) 0.75
Short-term enzalutamide treatment for the potential remission of active surveillance or intermediate-risk prostate cancer: a case study, review, and the need for a clinical trial. Res Rep Urol (2014) 0.75
Dose-dependent effects of small-molecule antagonists on the genomic landscape of androgen receptor binding. BMC Genomics (2012) 0.75
New secrets behind bone metastasis. Cell Res (2012) 0.75
Breast and prostate cancer: familial associations. Nat Rev Cancer (2010) 0.75
AR-Signaling in Human Malignancies: Prostate Cancer and Beyond. Cancers (Basel) (2017) 0.75
A Mutation in the Carbohydrate Recognition Domain Drives a Phenotypic Switch in the Role of Galectin-7 in Prostate Cancer. PLoS One (2015) 0.75
CHST9 rs1436904 genetic variant contributes to prognosis of triple-negative breast cancer. Sci Rep (2017) 0.75
Chitotriosidase, a marker of innate immunity, is elevated in patients with primary breast cancer. Cancer Biomark (2017) 0.75
Designing Dietary Recommendations Using System Level Interactomics Analysis and Network-Based Inference. Front Physiol (2017) 0.75
Non-conventional role of haemoglobin beta in breast malignancy. Br J Cancer (2017) 0.75
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet (2005) 42.90
The influence of finasteride on the development of prostate cancer. N Engl J Med (2003) 24.45
Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol (2002) 14.75
Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science (2009) 13.87
Cloning of a novel receptor expressed in rat prostate and ovary. Proc Natl Acad Sci U S A (1996) 10.94
Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol (2008) 10.91
Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. J Urol (2002) 8.73
A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest (2007) 8.54
AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. Science (1997) 8.05
Nuclear receptor coregulators: cellular and molecular biology. Endocr Rev (1999) 7.42
Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol (1996) 7.02
Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol (2009) 6.68
The androgen axis in recurrent prostate cancer. Clin Cancer Res (2004) 6.67
American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol (2004) 6.59
Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst (2004) 6.55
Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. Cancer Res (2008) 5.79
Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer. Clin Cancer Res (2005) 5.04
IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary gland. J Clin Invest (2007) 4.71
Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. J Natl Cancer Inst (2003) 4.45
Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583). J Clin Oncol (2004) 4.25
Pten in stromal fibroblasts suppresses mammary epithelial tumours. Nature (2009) 4.21
Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer (2009) 4.12
The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU Int (2008) 3.94
Inflammation and breast cancer. Balancing immune response: crosstalk between adaptive and innate immune cells during breast cancer progression. Breast Cancer Res (2007) 3.76
Gene expression profiling of the tumor microenvironment during breast cancer progression. Breast Cancer Res (2009) 3.52
Macrophage/cancer cell interactions mediate hormone resistance by a nuclear receptor derepression pathway. Cell (2006) 3.12
Targeting the androgen receptor: improving outcomes for castration-resistant prostate cancer. Endocr Relat Cancer (2004) 3.03
Clinical importance of estrogen receptor-beta evaluation in breast cancer patients treated with adjuvant tamoxifen therapy. J Clin Oncol (2008) 2.90
Macrophages induce invasiveness of epithelial cancer cells via NF-kappa B and JNK. J Immunol (2005) 2.81
Physiological action of progesterone in target tissues. Endocr Rev (1997) 2.73
Prostate cancer stem cells: a new target for therapy. J Clin Oncol (2008) 2.71
Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis. Ann Intern Med (2000) 2.65
Reactive stroma as a predictor of biochemical-free recurrence in prostate cancer. Clin Cancer Res (2003) 2.47
Prostatic hormonal carcinogenesis is mediated by in situ estrogen production and estrogen receptor alpha signaling. FASEB J (2007) 2.40
Hormonal, cellular, and molecular regulation of normal and neoplastic prostatic development. J Steroid Biochem Mol Biol (2004) 2.19
SRC-3 is required for prostate cancer cell proliferation and survival. Cancer Res (2005) 2.07
Interleukin-6 induces prostate cancer cell growth accompanied by activation of stat3 signaling pathway . Prostate (2000) 2.03
Androgen receptor inhibits estrogen receptor-alpha activity and is prognostic in breast cancer. Cancer Res (2009) 1.98
Androgen receptor coregulators and their involvement in the development and progression of prostate cancer. Int J Cancer (2007) 1.94
Identification of CDK10 as an important determinant of resistance to endocrine therapy for breast cancer. Cancer Cell (2008) 1.90
History of aromatase: saga of an important biological mediator and therapeutic target. Endocr Rev (2009) 1.88
Androgen-induced programs for prostate epithelial growth and invasion arise in embryogenesis and are reactivated in cancer. Oncogene (2008) 1.88
Expression of androgen receptors in primary breast cancer. Ann Oncol (2009) 1.85
IL-17 expression by breast-cancer-associated macrophages: IL-17 promotes invasiveness of breast cancer cell lines. Breast Cancer Res (2008) 1.80
Antiandrogen withdrawal in castrate-refractory prostate cancer: a Southwest Oncology Group trial (SWOG 9426). Cancer (2008) 1.73
Evaluation of androgen, estrogen (ER alpha and ER beta), and progesterone receptor expression in human prostate cancer by real-time quantitative reverse transcription-polymerase chain reaction assays. Cancer Res (2001) 1.72
Toremifene improves lipid profiles in men receiving androgen-deprivation therapy for prostate cancer: interim analysis of a multicenter phase III study. J Clin Oncol (2008) 1.72
A physiologic role for testosterone in limiting estrogenic stimulation of the breast. Menopause (2003) 1.71
C-reactive protein is significantly associated with prostate-specific antigen and metastatic disease in prostate cancer. BJU Int (2005) 1.69
PCPT: Evidence that finasteride reduces risk of most frequently detected intermediate- and high-grade (Gleason score 6 and 7) cancer. Urology (2009) 1.61
Endocrine and intracrine sources of androgens in women: inhibition of breast cancer and other roles of androgens and their precursor dehydroepiandrosterone. Endocr Rev (2003) 1.60
Androgens induce divergent proliferative responses in human breast cancer cell lines. J Steroid Biochem Mol Biol (1995) 1.58
Estrogen--the good, the bad, and the unexpected. Endocr Rev (2005) 1.57
Identification of SFRP1 as a candidate mediator of stromal-to-epithelial signaling in prostate cancer. Cancer Res (2005) 1.56
DNA replication licensing and progenitor numbers are increased by progesterone in normal human breast. Endocrinology (2009) 1.55
Steroid receptor coactivator-3/AIB1 promotes cell migration and invasiveness through focal adhesion turnover and matrix metalloproteinase expression. Cancer Res (2008) 1.54
Nuclear receptor coregulators in cancer biology. Cancer Res (2009) 1.51
CYP17 inhibition as a hormonal strategy for prostate cancer. Nat Clin Pract Urol (2008) 1.49
Mesenchymal-epithelial interactions: past, present, and future. Differentiation (2008) 1.47
The influence of chronic inflammation in prostatic carcinogenesis: a 5-year followup study. J Urol (2006) 1.45
Scottish adjuvant tamoxifen trial: a randomized study updated to 15 years. J Natl Cancer Inst (2001) 1.44
Molecular characterisation of the tumour microenvironment in breast cancer. Eur J Cancer (2008) 1.39
Expression of SRC-1, AIB1, and PEA3 in HER2 mediated endocrine resistant breast cancer; a predictive role for SRC-1. J Clin Pathol (2004) 1.38
Coassociation of estrogen receptor and p160 proteins predicts resistance to endocrine treatment; SRC-1 is an independent predictor of breast cancer recurrence. Clin Cancer Res (2009) 1.38
Increase of androgen-induced cell death and androgen receptor transactivation by BRCA1 in prostate cancer cells. Proc Natl Acad Sci U S A (2000) 1.36
CYP17 blockade by abiraterone: further evidence for frequent continued hormone-dependence in castration-resistant prostate cancer. Br J Cancer (2009) 1.33
Altered expression of androgen receptor in the malignant epithelium and adjacent stroma is associated with early relapse in prostate cancer. Cancer Res (2001) 1.32
Estrogen receptor-beta activated apoptosis in benign hyperplasia and cancer of the prostate is androgen independent and TNFalpha mediated. Proc Natl Acad Sci U S A (2010) 1.32
Toremifene increases bone mineral density in men receiving androgen deprivation therapy for prostate cancer: interim analysis of a multicenter phase 3 clinical study. J Urol (2007) 1.30
The dual, opposing roles of estrogen in the prostate. Ann N Y Acad Sci (2009) 1.29
Associations of high-grade prostate cancer with BRCA1 and BRCA2 founder mutations. Clin Cancer Res (2009) 1.29
Interleukin-8 is a paracrine inducer of fibroblast growth factor 2, a stromal and epithelial growth factor in benign prostatic hyperplasia. Am J Pathol (2001) 1.28
Breast cancer susceptibility gene 1 (BRCAI) is a coactivator of the androgen receptor. Cancer Res (2000) 1.27
Treating prostate cancer: a rationale for targeting local oestrogens. Nat Rev Cancer (2007) 1.27
Endocrine-induced regression of cancers. Cancer Res (1967) 1.21
Essential role for estrogen receptor beta in stromal-epithelial regulation of prostatic hyperplasia. Endocrinology (2006) 1.21
Control of androgen receptor signaling in prostate cancer by the cochaperone small glutamine rich tetratricopeptide repeat containing protein alpha. Cancer Res (2007) 1.20
Disruption of androgen receptor signaling by synthetic progestins may increase risk of developing breast cancer. FASEB J (2007) 1.19
IL-4 protects tumor cells from anti-CD95 and chemotherapeutic agents via up-regulation of antiapoptotic proteins. J Immunol (2004) 1.18
Estrogen and progesterone receptor proteins in breast cancer. Biochim Biophys Acta (1979) 1.16
A comprehensive association study for genes in inflammation pathway provides support for their roles in prostate cancer risk in the CAPS study. Prostate (2006) 1.15
Adjuvant hormonal therapy for breast cancer and risk of hormone receptor-specific subtypes of contralateral breast cancer. Cancer Res (2009) 1.14
Randomized trial of tamoxifen alone or combined with fluoxymesterone as adjuvant therapy in postmenopausal women with resected estrogen receptor positive breast cancer. North Central Cancer Treatment Group Trial 89-30-52. Breast Cancer Res Treat (2006) 1.13
Estrogen as therapy for breast cancer. Breast Cancer Res (2002) 1.10
Phase II study of ketoconazole plus granulocyte-macrophage colony-stimulating factor for prostate cancer: effect of extent of disease on outcome. J Urol (2007) 1.07
Prostatic tumor stroma: a key player in cancer progression. Curr Cancer Drug Targets (2008) 1.06
The androgen metabolite 5alpha-androstane-3beta,17beta-diol (3betaAdiol) induces breast cancer growth via estrogen receptor: implications for aromatase inhibitor resistance. Breast Cancer Res Treat (2008) 1.06
Prostaglandin E(2) stimulates prostatic intraepithelial neoplasia cell growth through activation of the interleukin-6/GP130/STAT-3 signaling pathway. Biochem Biophys Res Commun (2002) 1.05
E6-associated protein (E6-AP) is a dual function coactivator of steroid hormone receptors. Nucl Recept Signal (2008) 1.04
BRCA2 cooperates with histone acetyltransferases in androgen receptor-mediated transcription. Proc Natl Acad Sci U S A (2003) 1.03
Decreased BRCA1 confers tamoxifen resistance in breast cancer cells by altering estrogen receptor-coregulator interactions. Oncogene (2008) 1.02
BRCA2 mutations and androgen receptor expression as independent predictors of outcome of male breast cancer patients. Clin Cancer Res (2003) 1.01
Identification of molecular distinctions between normal breast-associated fibroblasts and breast cancer-associated fibroblasts. Cancer Microenviron (2009) 0.99
Steroid hormone receptor expression in male breast cancer. Eur J Surg Oncol (2005) 0.99
Exemestane: a review of its use in postmenopausal women with breast cancer. Drugs (2009) 0.98
Cooperation of p27(Kip1) and p18(INK4c) in progestin-mediated cell cycle arrest in T-47D breast cancer cells. Mol Cell Biol (2000) 0.95
Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol (2010) 13.03
Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med (2014) 11.05
Tumor antigen expression in melanoma varies according to antigen and stage. Clin Cancer Res (2006) 4.71
Targeting the androgen receptor: improving outcomes for castration-resistant prostate cancer. Endocr Relat Cancer (2004) 3.03
Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma. J Clin Oncol (2009) 2.88
Palifermin reduces the incidence of oral mucositis in patients with metastatic colorectal cancer treated with fluorouracil-based chemotherapy. J Clin Oncol (2006) 2.59
A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update. Eur J Cancer (2013) 2.51
Peptidomimetic targeting of critical androgen receptor-coregulator interactions in prostate cancer. Nat Commun (2013) 2.11
18F-fluorodeoxyglucose--positron emission tomography/computed tomography aids staging and predicts mortality in patients with muscle-invasive bladder cancer. Urology (2014) 2.09
Distinct nuclear receptor expression in stroma adjacent to breast tumors. Breast Cancer Res Treat (2013) 2.05
Androgen receptor inhibits estrogen receptor-alpha activity and is prognostic in breast cancer. Cancer Res (2009) 1.98
Evidence for efficacy of new Hsp90 inhibitors revealed by ex vivo culture of human prostate tumors. Clin Cancer Res (2012) 1.78
Thyrotoxicosis during sunitinib treatment for renal cell carcinoma. Clin Endocrinol (Oxf) (2008) 1.78
Structural and functional consequences of glutamine tract variation in the androgen receptor. Hum Mol Genet (2004) 1.74
Oncology health information quality on the Internet: a multilingual evaluation. Ann Surg Oncol (2011) 1.73
Androgen receptor driven transcription in molecular apocrine breast cancer is mediated by FoxA1. EMBO J (2011) 1.72
Cancer/testis antigens can be immunological targets in clonogenic CD133+ melanoma cells. Cancer Immunol Immunother (2009) 1.66
The regulatory T cell-associated transcription factor FoxP3 is expressed by tumor cells. Cancer Res (2008) 1.64
Dual roles of PARP-1 promote cancer growth and progression. Cancer Discov (2012) 1.63
A gene signature identified using a mouse model of androgen receptor-dependent prostate cancer predicts biochemical relapse in human disease. Int J Cancer (2012) 1.60
Therapeutic response to CDK4/6 inhibition in breast cancer defined by ex vivo analyses of human tumors. Cell Cycle (2012) 1.54
Tumor antigen processing and presentation depend critically on dendritic cell type and the mode of antigen delivery. Blood (2004) 1.54
Regulatory T-cell-mediated attenuation of T-cell responses to the NY-ESO-1 ISCOMATRIX vaccine in patients with advanced malignant melanoma. Clin Cancer Res (2009) 1.52
Contemporary management of renal cell carcinoma (RCC) in Victoria: implications for longer term outcomes and costs. BJU Int (2013) 1.50
Androgen receptor activity at the prostate specific antigen locus: steroidal and non-steroidal mechanisms. Mol Cancer Res (2003) 1.49
Uro-oncology multidisciplinary meetings at an Australian tertiary referral centre--impact on clinical decision-making and implications for patient inclusion. BJU Int (2014) 1.49
Discovery of circulating microRNAs associated with human prostate cancer using a mouse model of disease. Int J Cancer (2011) 1.46
Patterns of care for men diagnosed with prostate cancer in Victoria from 2008 to 2011. Med J Aust (2013) 1.43
Formation of hyaluronan- and versican-rich pericellular matrix by prostate cancer cells promotes cell motility. J Biol Chem (2007) 1.42
Immunohistochemical and molecular analysis of human melanomas for expression of the human cancer-testis antigens NY-ESO-1 and LAGE-1. Clin Cancer Res (2004) 1.41
Patterns of management and surveillance imaging amongst medical oncologists in Australia for stage I testicular cancer. BJU Int (2013) 1.39
IκBα mediates prostate cancer cell death induced by combinatorial targeting of the androgen receptor. BMC Cancer (2016) 1.39
The contribution of different androgen receptor domains to receptor dimerization and signaling. Mol Endocrinol (2008) 1.32
Suberoylanilide hydroxamic acid (vorinostat) represses androgen receptor expression and acts synergistically with an androgen receptor antagonist to inhibit prostate cancer cell proliferation. Mol Cancer Ther (2007) 1.32
Randomized trial of the combination of lomeguatrib and temozolomide compared with temozolomide alone in chemotherapy naive patients with metastatic cutaneous melanoma. J Clin Oncol (2007) 1.29
Role of adenosine receptors in regulating chemotaxis and cytokine production of plasmacytoid dendritic cells. Blood (2003) 1.25
IL-21 induces in vivo immune activation of NK cells and CD8(+) T cells in patients with metastatic melanoma and renal cell carcinoma. Cancer Immunol Immunother (2008) 1.22
Control of androgen receptor signaling in prostate cancer by the cochaperone small glutamine rich tetratricopeptide repeat containing protein alpha. Cancer Res (2007) 1.20
Expression of extracellular matrix components versican, chondroitin sulfate, tenascin, and hyaluronan, and their association with disease outcome in node-negative breast cancer. Clin Cancer Res (2004) 1.20
Circulating insulin-like growth factor-I and binding protein-3 and the risk of breast cancer. Cancer Epidemiol Biomarkers Prev (2007) 1.20
Disruption of androgen receptor signaling by synthetic progestins may increase risk of developing breast cancer. FASEB J (2007) 1.19
Circulating steroid hormone concentrations in postmenopausal women in relation to body size and composition. Breast Cancer Res Treat (2008) 1.19
Predicting clinical outcome through molecular profiling in stage III melanoma. Clin Cancer Res (2008) 1.17
Androgen receptor signaling: mechanism of interleukin-6 inhibition. Cancer Res (2004) 1.16
Melan-A-specific cytotoxic T cells are associated with tumor regression and autoimmunity following treatment with anti-CTLA-4. Clin Cancer Res (2009) 1.16
The impact of imiquimod, a Toll-like receptor-7 ligand (TLR7L), on the immunogenicity of melanoma peptide vaccination with adjuvant Flt3 ligand. Cancer Immun (2004) 1.15
Identification of novel androgen receptor target genes in prostate cancer. Mol Cancer (2007) 1.15
Circulating insulin-like growth factor-I and binding protein-3 and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev (2006) 1.15
A potential autocrine role for vascular endothelial growth factor in prostate cancer. Cancer Res (2002) 1.14
Circulating steroid hormone levels and risk of breast cancer for postmenopausal women. Cancer Epidemiol Biomarkers Prev (2010) 1.12
Immunodominant CD4+ responses identified in a patient vaccinated with full-length NY-ESO-1 formulated with ISCOMATRIX adjuvant. Proc Natl Acad Sci U S A (2004) 1.11
The Ludwig institute for cancer research Melbourne melanoma cell line panel. Pigment Cell Melanoma Res (2013) 1.08
Two phase I studies of low dose recombinant human IL-12 with Melan-A and influenza peptides in subjects with advanced malignant melanoma. Cancer Immun (2003) 1.08
Variants in the prostate-specific antigen (PSA) gene and prostate cancer risk, survival, and circulating PSA. Cancer Epidemiol Biomarkers Prev (2006) 1.07
Comparative biomarker expression and RNA integrity in biospecimens derived from radical retropubic and robot-assisted laparoscopic prostatectomies. Cancer Epidemiol Biomarkers Prev (2010) 1.07
Cancer-testis antigen expression in primary cutaneous melanoma has independent prognostic value comparable to that of Breslow thickness, ulceration and mitotic rate. Eur J Cancer (2010) 1.05
Global levels of specific histone modifications and an epigenetic gene signature predict prostate cancer progression and development. Cancer Epidemiol Biomarkers Prev (2010) 1.05
Positron emission tomography and molecular imaging of the prostate: an update. BJU Int (2006) 1.03
Directions in the immune targeting of cancer: lessons learned from the cancer-testis Ag NY-ESO-1. Immunol Cell Biol (2006) 1.03
Dynamic methylation of histone H3 at lysine 4 in transcriptional regulation by the androgen receptor. Nucleic Acids Res (2003) 1.03
ATP gradients inhibit the migratory capacity of specific human dendritic cell types: implications for P2Y11 receptor signaling. Blood (2003) 1.03
Decreased androgen receptor levels and receptor function in breast cancer contribute to the failure of response to medroxyprogesterone acetate. Cancer Res (2005) 1.02
Modulation of prostate cancer cell attachment to matrix by versican. Cancer Res (2003) 1.02
Co-expression of the androgen receptor and the transcription factor ZNF652 is related to prostate cancer outcome. Oncol Rep (2010) 1.02
Circulating microRNAs: macro-utility as markers of prostate cancer? Endocr Relat Cancer (2012) 1.02
A phase I biodistribution and pharmacokinetic trial of humanized monoclonal antibody Hu3s193 in patients with advanced epithelial cancers that express the Lewis-Y antigen. Clin Cancer Res (2007) 1.01
An open-label, single-arm phase two trial of gefitinib in patients with advanced or metastatic castration-resistant prostate cancer. Am J Clin Oncol (2009) 1.01
Phase I trial of 131I-huA33 in patients with advanced colorectal carcinoma. Clin Cancer Res (2005) 1.00
Ex vivo culture of human prostate tissue and drug development. Nat Rev Urol (2013) 1.00
Androgen receptor levels in prostate cancer epithelial and peritumoral stromal cells identify non-organ confined disease. Prostate (2005) 1.00
Flt3 ligand expands CD4+ FoxP3+ regulatory T cells in human subjects. Eur J Immunol (2012) 0.99
Tumor-specific isoform switch of the fibroblast growth factor receptor 2 underlies the mesenchymal and malignant phenotypes of clear cell renal cell carcinomas. Clin Cancer Res (2013) 0.98
Elevated levels of HER-2/neu and androgen receptor in clinically localized prostate cancer identifies metastatic potential. Prostate (2008) 0.98
Assessing regional hypoxia in human renal tumours using 18F-fluoromisonidazole positron emission tomography. BJU Int (2005) 0.97
Research resource: nuclear receptors as transcriptome: discriminant and prognostic value in breast cancer. Mol Endocrinol (2013) 0.97
A cancer vaccine induces expansion of NY-ESO-1-specific regulatory T cells in patients with advanced melanoma. PLoS One (2012) 0.96
A long, naturally presented immunodominant epitope from NY-ESO-1 tumor antigen: implications for cancer vaccine design. Cancer Res (2009) 0.94
PC-3 cells with enhanced androgen receptor signaling: a model for clonal selection in prostate cancer. Prostate (2004) 0.94
Intravesical chemotherapy plus bacille Calmette-Guérin in non-muscle invasive bladder cancer: a systematic review with meta-analysis. BJU Int (2012) 0.93
A robust human T-cell culture method suitable for monitoring CD8+ and CD4+ T-cell responses from cancer clinical trial samples. J Immunol Methods (2004) 0.93
Antiproliferative actions of the synthetic androgen, mibolerone, in breast cancer cells are mediated by both androgen and progesterone receptors. J Steroid Biochem Mol Biol (2008) 0.93
Peripheral primitive neuroectodermal tumor arising from the seminal vesicle. Urol Int (2008) 0.92
Hsp90: still a viable target in prostate cancer. Biochim Biophys Acta (2012) 0.92
Non-linear chromosomal inversion response in prostate after low dose X-radiation exposure. Mutat Res (2006) 0.92
Intratumoral genetic heterogeneity in metastatic melanoma is accompanied by variation in malignant behaviors. BMC Med Genomics (2013) 0.91
Positron emission tomography (PET), immuno-PET and radioimmunotherapy in renal cell carcinoma: a developing diagnostic and therapeutic relationship. BJU Int (2006) 0.91
5alpha-Reductase type 2 gene variant associations with prostate cancer risk, circulating hormone levels and androgenetic alopecia. Int J Cancer (2007) 0.91
Human perforin mutations and susceptibility to multiple primary cancers. Oncoimmunology (2013) 0.90
Investigation of hypoxia and carbonic anhydrase IX expression in a renal cell carcinoma xenograft model with oxygen tension measurements and ¹²⁴I-cG250 PET/CT. Urol Oncol (2009) 0.90
Intensity modulated radiation therapy dose painting for localized prostate cancer using ¹¹C-choline positron emission tomography scans. Int J Radiat Oncol Biol Phys (2012) 0.90
GRIP1 mediates the interaction between the amino- and carboxyl-termini of the androgen receptor. Biol Chem (2005) 0.90
Research resource: interplay between the genomic and transcriptional networks of androgen receptor and estrogen receptor α in luminal breast cancer cells. Mol Endocrinol (2012) 0.89
Positive surgical margins: rate, contributing factors and impact on further treatment: findings from the Prostate Cancer Registry. BJU Int (2014) 0.89
Therapeutic efficacy of 177Lu-CHX-A''-DTPA-hu3S193 radioimmunotherapy in prostate cancer is enhanced by EGFR inhibition or docetaxel chemotherapy. Prostate (2009) 0.89